Clinical Report: A Quick and Accessible Real-Time PCR Method for Detecting UBA1 Somatic Mutations in VEXAS Syndrome
Overview
This study validates a rapid allele-specific real-time PCR assay for detecting UBA1 mutations associated with VEXAS syndrome. The assay demonstrated high sensitivity and concordance with Sanger sequencing, enabling timely diagnosis.
Background
VEXAS syndrome is a severe autoinflammatory disease linked to somatic mutations in the UBA1 gene, primarily affecting older males. Early diagnosis is crucial due to the syndrome's high morbidity and mortality rates. Traditional sequencing methods may be limited in sensitivity and turnaround time, highlighting the need for more accessible diagnostic approaches.
Data Highlights
Method
Results
Real-time PCR
Identified UBA1 mutations in 5/6 (83.3%) suspected cases
Sanger Sequencing
Confirmed 100% concordance with PCR results
Key Findings
The allele-specific real-time PCR assay effectively detected UBA1 mutations in suspected VEXAS syndrome cases.
83.3% of patients with high clinical suspicion tested positive for UBA1 mutations.
There was 100% concordance between real-time PCR results and Sanger sequencing.
This method provides a rapid and cost-effective alternative to traditional sequencing techniques.
Real-time PCR can detect low-level somatic mutations with high sensitivity.
Clinical Implications
The rapid allele-specific real-time PCR assay offers a practical solution for clinicians to confirm VEXAS syndrome in patients with high clinical suspicion. This method can facilitate timely diagnosis and management, potentially improving patient outcomes.
Conclusion
The validated real-time PCR assay represents a significant advancement in the diagnostic approach for VEXAS syndrome, enabling rapid and reliable detection of critical UBA1 mutations.
by Luisa Agnello, Caterina Maria Gambino, Lidia La Barbera, Anna Masucci, Roberta Vassallo, Francesco Cacciabaudo, Mauro Midiri, Concetta Scazzone, Anna Maria Ciaccio, Giuliana Guggino, Marcello Ciaccio
